Raymond James raised the firm’s price target on AbbVie (ABBV) to $236 from $227 and keeps an Outperform rating on the shares. AbbVie delivered a very solid Q2 with nice top- and bottom-line beats, and raised 2025 guidance for the second time this year driven by the strong momentum with most key growth drivers like Skyrizi and Neuro, the analyst tells investors in a research note. Aesthetics was soft as anticipated and continues to be hampered by macro headwinds that are persisting, so it’s prudent to remain cautious with that franchise though AbbVie is still optimistic it will turn around longer-term, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
- AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
- AbbVie Reports Strong Q2 2025 Financial Results
- M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics
- Trump posts letters calling on drug company CEOs to lower prices